Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | 2026-03-03 13:30:28 | 93.07 | 0.83 | 0.91 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | 0001576280 | Guardant Health, Inc. | US40131M1099 | 254900M8C3E5VC8BR186 | 454139254 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 3100 HANOVER STREET | PALO ALTO | CA | 94304 | UNITED STATES | US | 855-698-8887 | 3100 HANOVER STREET, PALO ALTO, CA, 94304 | 3100 HANOVER STREET, PALO ALTO, CA, 94304 | — | Biotechnology | 2012 | Helmy Eltoukhy | 1,400 | http://guardanthealth.com | 6,200,000,000 | 130,635,301 | 131,170,441 | Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. | 2026-02-26 16:02:23 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 6,200,000,000 | 2,800,000,000 | 82.3529 | 131,170,441 | 7,749,000 | 6.2785 |
| 2024 | 3,400,000,000 | -700,000,000 | -17.0732 | 123,421,441 | 1,708,717 | 1.4039 |
| 2023 | 4,100,000,000 | 100,000,000 | 2.5 | 121,712,724 | 19,048,990 | 18.5547 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Darya Chudova | Chief Technology Officer | 2023 | 424,462 | 0 | 2,222,397 | 279,281 | 11,919 | 4,755,541 |
| Helmy Eltoukhy | Co-Chief Executive Officer, Chairman | 2023 | 1 | 0 | 0 | 0 | 11,590 | 11,591 |
| Amirali Talasaz | Co-Chief Executive Officer | 2023 | 1 | 0 | 0 | 0 | 26,414 | 26,415 |
| Michael Bell | Chief Financial Officer | 2023 | 482,000 | 0 | 1,851,413 | 327,375 | 9,900 | 4,123,993 |
| Craig Eagle | Chief Medical Officer | 2023 | 497,462 | 0 | 1,565,107 | 337,500 | 9,900 | 3,485,356 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 2,506 |
| 2024 | 2,021 |
| 2023 | 1,779 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 982,021,000 | 739,016,000 | 563,948,000 |
| Cost Of Revenue | 349,007,000 | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 364,191,000 | 347,753,000 | 367,194,000 |
| General And Administrative Expenses | 211,410,000 | 180,123,000 | 155,800,000 |
| Operating Expenses | 1,419,269,000 | 1,182,610,000 | 1,128,673,000 |
| Operating Income | -437,248,000 | -443,594,000 | -564,725,000 |
| Net Income | -416,277,000 | -436,373,000 | -479,449,000 |
| Earnings Per Share Basic | -3.32 | -3.56 | -4.28 |
| Earnings Per Share Diluted | -3.32 | -3.56 | -4.28 |
| Weighted Average Shares Outstanding Basic | 125,374,000 | 122,745,000 | 111,988,000 |
| Weighted Average Shares Outstanding Diluted | 125,374,000 | 122,745,000 | 111,988,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 378,203,000 | 525,540,000 | 1,133,537,000 |
| Marketable Securities Current | 823,395,000 | 314,438,000 | 35,097,000 |
| Accounts Receivable | 137,849,000 | 110,253,000 | 88,783,000 |
| Inventories | 85,876,000 | 71,083,000 | 61,948,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,466,046,000 | 1,055,114,000 | 1,347,106,000 |
| Marketable Securities Non Current | — | — | 98,002,000 |
| Property Plant And Equipment | 145,915,000 | 136,813,000 | 145,096,000 |
| Other Assets Non Current | 28,457,000 | 37,152,000 | 124,334,000 |
| Total Assets Non Current | 547,613,000 | 430,495,000 | 439,315,000 |
| Total Assets | 2,013,659,000 | 1,485,609,000 | 1,786,421,000 |
| Accounts Payable | 54,442,000 | 38,551,000 | 51,741,000 |
| Deferred Revenue | 50,753,000 | 35,468,000 | 17,965,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 77,889,000 | — | 187,952,000 |
| Total Liabilities Current | 302,730,000 | 225,583,000 | 205,917,000 |
| Long Term Debt | 1,504,000,000 | 1,142,547,000 | 1,139,966,000 |
| Other Liabilities Non Current | 127,773,000 | 92,834,000 | 96,006,000 |
| Total Liabilities Non Current | 1,810,236,000 | 1,399,673,000 | 1,421,820,000 |
| Total Liabilities | 2,112,966,000 | 1,625,256,000 | 1,627,737,000 |
| Common Stock | 1,000 | 1,000 | 1,000 |
| Retained Earnings | -2,994,512,000 | -2,578,235,000 | -2,141,862,000 |
| Accumulated Other Comprehensive Income | -4,852,000 | -5,201,000 | -3,675,000 |
| Total Shareholders Equity | -99,307,000 | -139,647,000 | 158,684,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 39,736,000 | 42,387,000 | 42,881,000 |
| Share Based Compensation Expense | 166,217,000 | 140,411,000 | 90,759,000 |
| Other Non Cash Income Expense | 294,000 | -2,228,000 | 1,182,000 |
| Change In Accounts Receivable | 28,175,000 | 21,389,000 | -8,378,000 |
| Change In Inventories | 14,792,000 | 9,135,000 | 10,350,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -212,000 | 2,375,000 | -1,298,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -184,760,000 | -239,858,000 | -324,975,000 |
| Purchases Of Marketable Securities | 818,231,000 | 307,323,000 | 629,902,000 |
| Sales Of Marketable Securities | 307,323,000 | 35,000,000 | 1,494,700,000 |
| Acquisition Of Property Plant And Equipment | 48,306,000 | 35,085,000 | 20,486,000 |
| Acquisition Of Business | 58,988,000 | — | — |
| Other Investing Activities | — | — | -1,531,000 |
| Cash From Investing Activities | -627,202,000 | -261,308,000 | 840,250,000 |
| Tax Withholding For Share Based Compensation | 30,535,000 | 15,681,000 | 11,197,000 |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | 257,128,000 | 0 | 493,116,000 |
| Repurchase Of Common Stock | 45,010,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 3,596,000 | -153,000 | 6,028,000 |
| Cash From Financing Activities | 671,133,000 | -996,000 | 477,375,000 |
| Change In Cash | -140,338,000 | -503,932,000 | 991,739,000 |
| Cash At End Of Period | 378,203,000 | 525,540,000 | 1,133,537,000 |
| Income Taxes Paid | 869,000 | 1,007,000 | 1,969,000 |
| Interest Paid | 3,771,000 | — | 2,578,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.32 | -3.56 | -4.28 |
| Price To Earnings Ratio | -30.7651 | -8.5815 | -6.3201 |
| Earnings Growth Rate | -6.7416 | -16.8224 | -33.2293 |
| Price Earnings To Growth Ratio | 4.5635 | 0.5101 | 0.1902 |
| Book Value Per Share | -0.7921 | -1.1377 | 1.417 |
| Price To Book Ratio | -128.9506 | -26.8524 | 19.09 |
| Ebitda | -371,775,000 | -390,398,000 | -432,021,000 |
| Enterprise Value | 13,931,497,360 | 4,366,866,750 | 3,035,704,400 |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | -15.145 | -8.1817 | 7.1839 |
| Capital Expenditures | 48,838,000 | 34,104,000 | 20,057,000 |
| Free Cash Flow | -233,598,000 | -273,962,000 | -345,032,000 |
| Return On Equity | 4.1918 | 3.1248 | -3.0214 |
| One Year Beta | 1.0618 | 1.5288 | 1.6823 |
| Three Year Beta | 1.3108 | 1.9869 | 1.9129 |
| Five Year Beta | 1.6532 | 1.3605 | 1.3788 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Krognes Steve E. | Director | 2026-02-28 | 154 | A | 19,053 |
| Krognes Steve E. | Director | 2026-02-28 | 154 | D | 618 |
| MIGNONE ROBERTO | Director | 2026-02-21 | 264 | A | 4,223 |
| MIGNONE ROBERTO | Director | 2026-02-21 | 264 | D | 8,448 |
| Hidalgo Medina Manuel | Director | 2026-02-17 | 232 | A | 1,493 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Sheldon Whitehouse | Senator | 2025-12-01 | Purchase | 2025-11-21 | Self | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Strategic Investment Solutions, Inc. /IL | 2025-12-31 | 2,043 | 20 | 102.15 |
| TD Capital Management LLC | 2025-12-31 | 817 | 8 | 102.125 |
| Bell Investment Advisors, Inc | 2025-12-31 | 5,618 | 55 | 102.1455 |
| Beaird Harris Wealth Management, LLC | 2025-12-31 | 1,022 | 10 | 102.2 |
| MV CAPITAL MANAGEMENT, INC. | 2025-12-31 | 3,167 | 31 | 102.1613 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| LAZARD FUNDS INC | 2025-12-31 | Open Shares | LEOOX | 8 | 1,480 | 0.0025 |
| LAZARD FUNDS INC | 2025-12-31 | Institutional Shares | LEOIX | 8 | 1,480 | 0.0025 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCFX | 15,544 | 1,587,664.16 | 1.4565 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYBOX | 15,544 | 1,587,664.16 | 1.4565 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYOAX | 15,544 | 1,587,664.16 | 1.4565 |